Clinical trial · Interventional
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
Prospective Phase II Study of Stereotactic Body Proton Therapy for Treatment of PrimAry Renal Cell Carcinoma (SPARE)
NCT06376669CI-TRIAL-00107268SPARErecruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Proton Stereotactic Body Radiation therapy (SBRT) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Proton Stereotactic Body Radiation Therapy (SBRT)
- description
- The SBRT group is the single arm of this study.
- interventionNames
- Radiation: Proton Stereotactic Body Radiation therapy (SBRT)
Primary outcomes (2)
- measure
- Change in kidney function after PROTON-BASED SBRT treatment as assessed by serum creatine levels
- timeFrame
- Baseline and every 3-6 months up to 2 years post treatment
- description
- Change in serum creatine levels from Baseline visit.
- measure
- Change in kidney function after PROTON-BASED SBRT treatment as assessed by estimated glomerular rate (eGFR) values
- timeFrame
- Baseline and every 3-6 months up to 2 years post treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years 2. Biopsy proven renal cell carcinoma. 3. No clinical or radiographic evidence of metastatic disease. 4. Not a candidate for surgical treatment or local ablative procedures. 5. Subjects are able to undergo either an MRI or administration of contrast agent for CT. Exclusion Criteria: 1. Prior history of radiation treatment with overlapping fields. 2. Patients with proven metastatic disease. 3. Female subjects who are pregnant or planning to become pregnant during the treatment.
References
Publications (1)
- DERIVEDShaaban SG, Chen H, Singla N, Tran A, Hu C, Ke S, Jarrett TW, Deville C. Prospective phase II study of stereotactic body proton therapy for treatment of primary renal cell carcinoma (SPARE): clinical trial protocol. BMC Cancer. 2025 Jul 1;25(1):1107. doi: 10.1186/s12885-025-14486-1. PMID 40597914